In 2024, the FDA is looking at copyright for therapeutic use together with psychological intervention in individuals with PTSD, given that the agency has accepted an application from Lykos Therapeutics."The SAP is only available for certain severe health-related situations, is intended for unexpected emergency basis only, and clients simply cannot